EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer by Yuanzhou Zhang, Xiaojun Zhang, Xupeng Yang, Xingshi Chen, Yuehong Wang, Jingying Hu, Rui Liu, Xiaoying Luo

“…The study provides new insights into the metabolic adaptations of DTP lung cancer cells in response to EGFR‐TKIs, offering novel therapeutic strategies for targeting these persister cells.…”
Get full text

METTL16-dependent GPX4 m6A modification links ferroptosis to NSCLC TKIs resistance by Yingou Zeng, Qiang Wang, Di Qiao, Bin Dai, Yunlong Wu, Meng Wang, Zhe Fan, Jia Chen

“…Abstract Background Non-small-cell lung cancer (NSCLC) is a highly aggressive cancer with a poor prognosis, largely due to increasing resistance to Tyrosine Kinase Inhibitors (TKIs). The mechanisms of NSCLC TKI resistance remain unknown. …”
Get full text

Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma by Pritsana Raungrut, Wararat Chiangjong, Thipphanet Masjon, Saowanee Maungchanburi, Thidarat Ruklert, Narongwit Nakwan

Subjects: Get full text

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, singl... by Xiaochun Chen, Changping Wang, Yuanjie Tang, Haoyan Sun, Hongling Liu, Chuan Lin, Zhiping Yuan

Subjects: Get full text

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models by Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago‐Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam, Tomer‐Meir Salame, Moshit Lindzen, Yosef Yarden

Subjects: “…EGFR TKIs…”
Get full text

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study by Yin Pan, Meichen Li, Mingjie Yu, Jing Chen, Hui Yu, Kaijing Liu, Likun Chen

“…Introduction: Third-generation EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes in EGFR-mutant non–small cell lung cancer (NSCLC), but resistance occurs, especially in patients with Brain metastases (BMs). …”
Get full text

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes by Meng Zhang, Lan Wang, Qi Wang, Tian-Hui Guo, Wen Gao, Bi-Yuan Zhang, Hai-Ji Wang

Subjects: “…Tyrosine kinase inhibitors (TKIs)…”
Get full text

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR by Tao Yu, Qian Xia, Ting Gong, Jing Wang, DianSheng Zhong

Subjects: Get full text

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment by Nicha Zungsontiporn, Korakot Srianuwattipong, Sakun Santisukwongchote, Piyada Sitthideatphaiboon, Poonchavist Chantranuwat, Chatchawit Aporntewan, Chanida Vinayanuwattikun

Subjects: Get full text

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database by Zongwei Tang, Haichi Song, Lingyun Pan, Min Zhang, Siyu Li, Wenrui Li, Wanyi Chen, Xiaoxiao Wang

“…Abstract Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) represent a class of targeted drugs that have changed the cancer therapy landscape. …”
Get full text

Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI gener... by Ryan Cooper, Dhruv Ramaswami, Jacob S. Thomas, Jorge J. Nieva, Robert Hsu

“…Methods 151 patients treated with EGFR TKIs in Los Angeles were grouped according to generation of TKI. …”
Get full text

The inhibitory effect of tyrosine kinase inhibitors on angiogenesis in zebrafish and interrelationship with the activation of the PI3K/AKT pathway by Lili Yang, Xiaotian Liu

“…Abstract Background To evaluate the effects of tyrosine kinase inhibitors (TKIs) Dovitinib, Lapatinib, and Telatinib on angiogenesis in zebrafish, and to explore the regulatory mechanism of PI3K/AKT pathway activator SC79 on these inhibitory effects. …”
Get full text

Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical... by Hsiang-Wen Lin, Tien-Chao Lin, Chien-Ning Hsu, Tzu-Pei Yeh, Yu-Chieh Chen, Liang-Chih Liu, Chen-Yuan Lin

“…This study aimed to develop an optimal prediction model for QTc prolongation risk and estimate its risk probability in cancer patients treated with oral tyrosine kinase inhibitors (TKIs). Methods This retrospective cohort study analyzed electronic medical records (EMR) of cancer patients newly treated with commonly used oral TKIs at a medical center between January 2016 and December 2020. …”
Get full text

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System by Shota Yanagida, Hiroyuki Kawagishi, Mitsuo Saito, Hirofumi Hamano, Yoshito Zamami, Yasunari Kanda

“…Next, we examined the real‐world data of the EGFR‐TKIs using FDA Adverse Event Reporting System (FAERS; JAPIC AERS). …”
Get full text

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients by Xiaodong Chai, Hongxia Li, Moxuan Yang, Junyang Zeng, Genxiu Chen, Yongmeng Li, Wei Wang, Zichen Liu, Kun Li, Tongmei Zhang, Shuhao Wang, Nanying Che

“…Abstract Background Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with EGFR mutations. …”
Get full text

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis by Sumanta Pal, Paulo Gustavo Bergerot, Nazli Dizman, JoAnn Hsu, Yung Lyou, Nicholas Salgia, Daniel Enriquez, Tyler Izatt, Jeffrey M Trent, Sara Byron

“…We sought to determine genomic predictors of differential response to vascular endothelial growth factor–tyrosine kinase inhibitors (VEGF-TKIs) and IO.Methods Consecutive patients who underwent genomic profiling were identified; patients receiving either VEGF-TKIs or IO were included. …”
Get full text

Modern treatment of ALK-positive non-small cell lung cancer by D. A. Kharagezov, Yu. N. Lazutin, E. A. Mirzoyan, A. G. Milakin, O. N. Stateshny, I. A. Leyman, M. A. Gappoeva, V. N. Vitkovskaya, K. D. Iozefi

“…Non-small cell lung cancer (NSCLC) with chromosomal rearrangement of anaplastic lymphoma kinase (ALK) is sensitive to targeted therapy with tyrosine kinase inhibitors (TKIs). Tumor cells containing ALK fusion are sensitive to TKIs – targeted drugs that have significantly improved the results of treatment of patients with ALK-positive NSCLC, half of whom survive more than 6.8 years after diagnosis. …”
Get full text

miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling by Cristina Migliore, Elena Morando, Elena Ghiso, Sergio Anastasi, Vera P Leoni, Maria Apicella, Davide Cora', Anna Sapino, Filippo Pietrantonio, Filippo De Braud, Amedeo Columbano, Oreste Segatto, Silvia Giordano

“…MiRNA profiling combined with RNA‐Seq in MET‐addicted cancer cell lines led us to identify the miR‐205/ERRFI1 (ERBB receptor feedback inhibitor‐1) axis as a novel mediator of resistance to MET tyrosine kinase inhibitors (TKIs). In cells resistant to MET‐TKIs, epigenetically induced miR‐205 expression determined the downregulation of ERRFI1 which, in turn, caused EGFR activation, sustaining resistance to MET‐TKIs. …”
Get full text

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations by Han X, You Y, Guo X, Ji Y, Nie K

“…EGFR tyrosine kinase inhibitors (TKIs) were the first-line treatment in all patients. …”
Get full text

Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven‐Year‐Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review by Aziz Eghbali, Mobin Obeidinia, Hamideh Sadat Mirmohammadi, Roghayeh Rahimiafazal, Arya Shirani

“…Recent studies, nonetheless, suggest that tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) may be effective treatment options. …”
Get full text